The objective of this prospective study was to examine the exposure to the main active metabolites of ciprofloxacin in critically ill patients and to examine the factors (demographic, laboratory and genetic) that could potentially affect the drug metabolic conversion of ciprofloxacin. The secondary aim was to develop a population pharmacokinetic model for the metabolite showing the most associations with the abovementioned factors. A total of 29 patients were treated with intravenous infusion of ciprofloxacin and enrolled on this trial. Blood samples for pharmacokinetic analysis were taken at 1, 4, and 11.5 h following the completion of the infusion. Sex, age, body weight, height, serum creatinine and bilirubin levels, and creatinine clearance (CLCR) were recorded, and polymorphisms rs2032582 and rs1045642 in the ABCB1 gene, rs4148977 in the SLCO1A2 gene and rs762551 in the CYP1A2 gene were analyzed. A three-stage parent drug-metabolite population pharmacokinetic model was developed. Median (IQR) metabolite/parent ratios of the desethylene ciprofloxacin, formyl ciprofloxacin and oxociprofloxacin were 5.86 (4.09-9.87)%, 4.08 (3.38-6.92)% and 5.91 (3.42-13.65)%, respectively. The desethylene ciprofloxacin metabolic ratio was positively associated with height (r2 = 0.2277, p = 0.0089) and CLCR (r2 = 0.2023, p = 0.0144) and negatively associated with age (r2 = 0.2227, p = 0.0112). Males had a significantly higher oxociprofloxacin metabolic ratio than females (9.14 vs 3.42%, p = 0.0043). In the desethylene ciprofloxacin population PK model, the volume of distribution decreased with age, the parent drug-metabolite transfer rate constant increased with CLCR, and the metabolite elimination rate constant decreased with age and is increased in CYP1A2 rs762551 variant allele carriers. We therefore hypothesized that the CYP1A2 inhibition by ciprofloxacin is mediated by its metabolite desethylene ciprofloxacin.

Department of Anesthesiology and ICM 2nd Faculty of Medicine Charles University and Motol University Hospital 150 06 Prague Czech Republic

Department of Pharmacology 1st Faculty of Medicine Charles University and General University Hospital 128 00 Prague Czech Republic

Forensic Laboratory of Biologically Active Substances Department of Chemistry of Natural Compounds University of Chemistry and Technology 166 28 Prague Czech Republic

Zobrazit více v PubMed

Roberts J.A., Alobaid A.S., Wallis S.C., Perner A., Lipman J., Sjovall F. Defining optimal dosing of ciprofloxacin in patients with septic shock. J. Antimicrob. Chemother. 2019;74:1662–1669. doi: 10.1093/jac/dkz069. PubMed DOI

Abdulla A., Rogouti O., Hunfeld N.G.M., Endeman H., Dijkstra A., van Gelder T., Muller A.E., de Winter B.C.M., Koch B.C.P. Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients. Eur. J. Clin. Pharmacol. 2020;76:957–967. doi: 10.1007/s00228-020-02873-5. PubMed DOI PMC

Al-Omar M.A. Ciprofloxacin: Drug metabolism and pharmacokinetic profile. Profiles Drug Subst. Excip. Relat. Methodol. 2005;31:209–214. PubMed

Sharma P.C., Jain A., Jain S., Pahwa R., Yar M.S. Ciprofloxacin: Review on developments in synthetic, analytical, and medicinal aspects. J. Enzyme Inhib. Med. Chem. 2010;25:577–589. doi: 10.3109/14756360903373350. PubMed DOI

Bergan T. Extravascular penetration of ciprofloxacin. A review. Diagn. Microbiol. Infect. Dis. 1990;13:103–114. doi: 10.1016/0732-8893(90)90093-B. PubMed DOI

Bergan T., Dalhoff A., Rohwedder R. Pharmacokinetics of ciprofloxacin. Infection. 1988;16((Suppl. S1)):S3–S13. doi: 10.1007/BF01650500. PubMed DOI

Vance-Bryan K., Guay D.R., Rotschafer J.C. Clinical pharmacokinetics of ciprofloxacin. Clin. Pharmacokinet. 1990;19:434–461. doi: 10.2165/00003088-199019060-00003. PubMed DOI

Zeiler H.J., Petersen U., Gau W., Ploschke H.J. Antibacterial activity of the metabolites of ciprofloxacin and its significance in the bioassay. Arzneimittelforschung. 1987;37:131–134. PubMed

Bolhuis M.S., Panday P.N., Pranger A.D., Kosterink J.G., Alffenaar J.W. Pharmacokinetic drug interactions of antimicrobial drugs: A systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams. Pharmaceutics. 2011;3:865–913. doi: 10.3390/pharmaceutics3040865. PubMed DOI PMC

Park M.S., Okochi H., Benet L.Z. Is Ciprofloxacin a Substrate of P-glycoprotein? Arch. Drug Inf. 2011;4:1–9. doi: 10.1111/j.1753-5174.2010.00032.x. PubMed DOI PMC

Xiao Y., Deng J., Liu X., Huang J., Sun Y., Dai R., Hong M. Different binding sites of bovine organic anion-transporting polypeptide1a2 are involved in the transport of different fluoroquinolones. Drug Metab. Dispos. 2014;42:1261–2617. doi: 10.1124/dmd.114.057448. PubMed DOI

Traynor J., Mactier R., Geddes C.C., Fox J.G. How to measure renal function in clinical practice. BMJ. 2006;333:733–737. doi: 10.1136/bmj.38975.390370.7C. PubMed DOI PMC

Sima M., Michalickova D., Rysanek P., Cihlarova P., Kuchar M., Lzicarova D., Berousek J., Hartinger J.M., Vymazal T., Slanar O. No Time Dependence of Ciprofloxacin Pharmacokinetics in Critically Ill Adults: Comparison of Individual and Population Analyses. Pharmaceutics. 2021;13:1156. doi: 10.3390/pharmaceutics13081156. PubMed DOI PMC

Pechandova K., Buzkova H., Slanar O., Perlik F. Polymorphisms of the MDR1 gene in the Czech population. Folia Biol. 2006;52:184–189. PubMed

Allard S., Kinzig M., Boivin G., Sorgel F., LeBel M. Intravenous ciprofloxacin disposition in obesity. Clin. Pharmacol. Ther. 1993;54:368–373. doi: 10.1038/clpt.1993.162. PubMed DOI

Frost R.W., Lettieri J.T., Krol G., Shamblen E.C., Lasseter K.C. The effect of cirrhosis on the steady-state pharmacokinetics of oral ciprofloxacin. Clin. Pharmacol. Ther. 1989;45:608–616. doi: 10.1038/clpt.1989.81. PubMed DOI

Bergan T., Thorsteinsson S.B., Rohwedder R., Scholl H. Elimination of ciprofloxacin and three major metabolites and consequences of reduced renal function. Chemotherapy. 1989;35:393–405. doi: 10.1159/000238702. PubMed DOI

Giannouchos T.V., Gomez-Lumbreras A., Malone D.C. Risk of tizanidine-induced adverse events after concomitant exposure to ciprofloxacin: A cohort study in the U.S. Am. J. Emerg. Med. 2022;55:147–151. doi: 10.1016/j.ajem.2022.03.008. PubMed DOI

Bachmann F., Meyer Zu Schwabedissen H.E., Duthaler U., Krahenbuhl S. Cytochrome P450 1A2 is the most important enzyme for hepatic metabolism of the metamizole metabolite 4-methylaminoantipyrine. Br. J. Clin. Pharmacol. 2022;88:1885–1896. doi: 10.1111/bcp.15108. PubMed DOI PMC

Brouwers E.E., Sohne M., Kuipers S., van Gorp E.C., Schellens J.H., Koks C.H., Beijnen J.H., Huitema A.D. Ciprofloxacin strongly inhibits clozapine metabolism: Two case reports. Clin. Drug Investig. 2009;29:59–63. doi: 10.2165/0044011-200929010-00006. PubMed DOI

Jokinen M.J., Olkkola K.T., Ahonen J., Neuvonen P.J. Effect of ciprofloxacin on the pharmacokinetics of ropivacaine. Eur. J. Clin. Pharmacol. 2003;58:653–657. doi: 10.1007/s00228-002-0540-8. PubMed DOI

Batty K.T., Davis T.M., Ilett K.F., Dusci L.J., Langton S.R. The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects. Br. J. Clin. Pharmacol. 1995;39:305–311. doi: 10.1111/j.1365-2125.1995.tb04453.x. PubMed DOI PMC

Healy D.P., Polk R.E., Kanawati L., Rock D.T., Mooney M.L. Interaction between oral ciprofloxacin and caffeine in normal volunteers. Antimicrob. Agents Chemother. 1989;33:474–478. doi: 10.1128/AAC.33.4.474. PubMed DOI PMC

Zhang L., Wei M.J., Zhao C.Y., Qi H.M. Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes. Acta Pharmacol. Sin. 2008;29:1507–1514. doi: 10.1111/j.1745-7254.2008.00908.x. PubMed DOI

Dose Optimization and Targeting Strategies of Anti-Infective Agents